You can order your free Resource Kit by providing your mailing information below. If you wish, you also may sign up to receive future information from Reckitt Benckiser Pharmaceuticals about treating opioid dependence with SUBOXONE (buprenorphine/naloxone). SUBOXONE is a prescription medicine that is used in a doctor's office to treat opioid dependence.

Important Safety Information

SUBOXONE® (buprenorphine HCl/naloxone HCl dihydrate CIII sublingual tablets) is indicated for the treatment of opioid dependence.

Buprenorphine, particularly when taken by the intravenous route, in combination with benzodiazepines or other CNS depressants (including alcohol) has been associated with significant respiratory depression and death.

SUBOXONE has potential for abuse and produces dependence of the opioid type, with a milder withdrawal syndrome than full agonists.

Cytolytic hepatitis and hepatitis with jaundice have been observed in the addicted population receiving buprenorphine.

There are no adequate and well-controlled studies of SUBOXONE (a Category C medication) in pregnancy.

Caution should be exercised when driving cars or operating machinery.

Always store buprenorphine-containing medications safely and out of the reach and sight of children. Destroy any unused medication appropriately.

The most commonly reported adverse events with SUBOXONE include: headache (36%, placebo 22%), withdrawal syndrome (25%, placebo 37%), pain (22%, placebo 19%), insomnia (14%, placebo 16%), nausea (15%, placebo 11%), and constipation (12%, placebo 3%). Please see full Prescribing Information for a complete list.

To report an adverse event caused by taking SUBOXONE, please call 1-877-782-6966.

You are also encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.